Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

242.67 +0.24 (+0.10%)
Streaming Delayed Price Updated: 11:02 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-... 
Via Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts... 
Via Talk Markets
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss... 
Via Benzinga
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY... 
Via Benzinga
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops
Patients who received the drug didn't improve in the six-minute walking test. 
Via Investor's Business Daily
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is... 
Via Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.